The Alzheimer's Association estimates that 5.3 million Americans have
Alzheimer's Disease, a form of dementia, and projects a 74% increase
over the next 15 years. Furthermore, Alzheimer's is the seventh leading
cause of death in the U.S.
It is generally accepted that treatments for Alzheimer's Disease will be much more effective if introduced prior to the onset of symptoms and before significant brain destruction occurs. However, until now researchers could not study treatments to prevent Alzheimer's Disease because they had no way of knowing who would develop it. Well, all this is about to change…
Join MNI neurologist Paul Schulz, M.D., from noon to 1 p.m. on Tuesday, July 31 to learn about the use of a new diagnostic tool, called amyloid imaging, where an FDA-approved agent called Amyvid binds to abnormal proteins in the brain, allowing physicians, for the first time ever, to diagnose Alzheimer's Diseasedefinitively. This screening tool could also provide researchers with the insight they need to one day prevent Alzheimer's Disease.
Dr. Paul E. Schulz is affiliated with Memorial Hermann Health System.
Views or opinions presented in this video are solely those of the physician(s) or presenter(s) and do not necessarily represent the views and opinions of Memorial Hermann Health System. This video is presented to the public for educational purposes only and Memorial Hermann Health System is not responsible for its content. Patients should consult a physician regarding the diagnosis and treatment of any medical condition.